Doc code :IDS Doc description: Information Disclosure Statement (IDS) Filed

Offination Disclosure Statement (IDS) Filed

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Application Number 10697655 Filing Date 2003-10-31 First Named Inventor Michael Weller Art Unit 1615 Examiner Name Klinkel, Kortney L Attorney Docket Number NGIO-001

U.S.PATENTS							Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1	6127393		2000-10-03	FERNANDEZ				
	2	6407125		2002-06-18	FERNANDEZ				
	3	6407139		2002-06-18	ISAJI				
If you wish	n to ac	dd additional U.S. Paten	t citatio	n information p	lease click the Add button.	l	Add		
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1	20020128290		2002-09-12	OHSHIMA ETSUO				
	2	20050239892		2005-10-27	MEYDANI				
	3	20060011443		2006-05-25	FUKUSHIMA				
If you wish	n to ac	ı dd additional U.S. Publis	hed Ap	plication citatio	। n information please click the Add	d button	Add		
				FOREIGN PAT	TENT DOCUMENTS		Remove		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10697655		
Filing Date		2003-10-31		
First Named Inventor Micha		nel Weller		
Art Unit		1615		
Examiner Name Klinke		el, Kortney L		
Attorney Docket Number		NGIO-001		

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5	
	1	2 495 952	CA		2004-03-04	KISSEI PHARMACEUTICAL			
	2	1369114	EP		2002-06-07	TERNESS			
	3	2003-026575	JP		2003-01-29	ROHTO PHARMA			
	4	2005-089345	JP		2003-09-16	TENDOU			
	5	2006/053390	wo		2006-05-26	ANGIOGEN PHARMACEUTICALS			
If you wisl	n to ac	dd additional Foreign P	atent Document	citation	information pl	lease click the Add buttor		•	
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove		
Examiner Initials*	aminer Cite No Cite No Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						T 5		
	1	AZUMA, H. et al. (1976) "Pharmacological properties of N-(3',4'-dimethoxycinnamoyl) anthranilic acid (N-5'), a new anti-atopic agent." Br. J. Pharmac.58: 483-488.							
	2	FALLARINO, F.; et al, "T cell apoptosis by tryptophan catabolism", Cell Death and Differentiation, 2002, 9 (10):1069-1077.							
	3	MOFFETT, JR et al. (2003) "Tryptophan and the immune response" Immunology and Cell Biology 81(4):247-265.							

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10697655
Filing Date		2003-10-31
First Named Inventor Micha		nel Weller
Art Unit		1615
Examiner Name Klinke		el, Kortney L
Attorney Docket Number		NGIO-001

	4	PLATTEN, M. et al (2005) "Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite." Science 310:850-855.							
	5	SHIGEKI, S et al. (1997) "Treatment of Keloid and Hypertrophic scares by iontophoretic transdermal delivery of translast." Scan J. Reconstr Hand Surg. 31(2):151-158.							
	6	TERNESS, P.; et al, "Inhibition of allogeneic T cell proliferation by indoleamine-2, 3-dioxygenase-expressing dentritic cells: Mediation of suppression by tryptophan metabolites", Journal of Experimental Medicine, 19 August 2002, 196 (4):447-457.							
	7	WIDNER, B., et al, "Tryptophan degradation to control T-cell responsiveness", Immunology Today, May 2000, 21 (5):250.							
	8	WIRLEITNER, B., et al., "Interferon-gamma-induced conversion of tryptophan: immunologic and neuropsychiatric aspects", Current Medicinal Chemistry, 2003, 10(16):1581-1591.							
If you wish to add additional non-patent literature document citation information please click the Add button Add									
		EXAMINER SIGNATURE							
Examiner	Signa	ure Date Considered							
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									
¹ See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.									